Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)

NCT01147211 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: MK2206

Sponsor

National Taiwan University Hospital